Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
- PMID: 17554711
- DOI: 10.1086/518619
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
Abstract
Background: Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment.
Methods: We studied associations of new-onset diabetes mellitus with hepatitis B virus and hepatitis C virus coinfections and antiretroviral therapy in participants in the Swiss HIV Cohort Study, using Poisson regression.
Results: A total of 123 of 6513 persons experienced diabetes mellitus during 27,798 person-years of follow-up (PYFU), resulting in an incidence of 4.4 cases per 1000 PYFU (95% confidence interval [CI], 3.7-5.3 cases per 1000 PYFU). An increased incidence rate ratio (IRR) was found for male subjects (IRR, 2.5; 95% CI, 1.5-4.2), older age (IRR for subjects >60 years old, 4.3; 95% CI, 2.3-8.2), black (IRR, 2.1; 95% CI, 1.1-4.0) and Asian (IRR, 4.9; 95% CI, 2.2-10.9) ethnicity, Centers for Disease Control and Prevention disease stage C (IRR, 1.6; 95% CI, 1.04-2.4), and obesity (IRR, 4.7; 95% CI, 3.1-7.0), but results for hepatitis C virus infection or active hepatitis B virus infection were inconclusive. Strong associations were found for current treatment with nucleoside reverse-transcriptase inhibitors (IRR, 2.22; 95% CI, 1.11-4.45), nucleoside reverse-transcriptase inhibitors plus protease inhibitors (IRR, 2.48; 95% CI, 1.42-4.31), and nucleoside reverse-transcriptase inhibitors plus protease inhibitors and nonnucleoside reverse-transcriptase inhibitors (IRR, 3.25; 95% CI, 1.59-6.67) but were not found for treatment with nucleoside reverse-transcriptase inhibitors plus nonnucleoside reverse-transcriptase inhibitors (IRR, 1.47; 95% CI, 0.77-2.82).
Conclusions: In addition to traditional risk factors, current treatment with protease inhibitor- and nucleoside reverse-transcriptase inhibitor-containing regimens was associated with the risk of developing type 2 diabetes mellitus. Our study did not find a significant association between viral hepatitis infection and risk of incident diabetes.
Similar articles
-
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.Clin Infect Dis. 2010 Feb 15;50(4):502-11. doi: 10.1086/649922. Clin Infect Dis. 2010. PMID: 20085465
-
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.AIDS. 2003 May 23;17(8):1179-93. doi: 10.1097/01.aids.0000060358.78202.c1. AIDS. 2003. PMID: 12819520
-
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.AIDS. 2006 Oct 3;20(15):1941-50. doi: 10.1097/01.aids.0000247115.81832.a1. AIDS. 2006. PMID: 16988515
-
[HIV infection, antiretroviral therapy, and endothelium].Herz. 2005 Sep;30(6):472-80. doi: 10.1007/s00059-005-2740-3. Herz. 2005. PMID: 16170677 Review. German.
-
Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.Pharmacotherapy. 2005 Aug;25(8):1068-72. doi: 10.1592/phco.2005.25.8.1068. Pharmacotherapy. 2005. PMID: 16207097 Review.
Cited by
-
Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916. Antivir Ther. 2012. PMID: 22267473 Free PMC article.
-
Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study.BMC Endocr Disord. 2023 Jul 28;23(1):160. doi: 10.1186/s12902-023-01419-x. BMC Endocr Disord. 2023. PMID: 37507703 Free PMC article.
-
State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors.J Gen Intern Med. 2011 Dec;26(12):1426-33. doi: 10.1007/s11606-011-1807-5. Epub 2011 Aug 12. J Gen Intern Med. 2011. PMID: 21837376 Free PMC article.
-
Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):538-46. doi: 10.1097/QAI.0000000000000354. J Acquir Immune Defic Syndr. 2014. PMID: 25393940 Free PMC article.
-
Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Curr HIV/AIDS Rep. 2015 Dec;12(4):375-87. doi: 10.1007/s11904-015-0284-6. Curr HIV/AIDS Rep. 2015. PMID: 26423407 Review.